GI Oncology standard regimen doses remain too high for many real world patients. Retrospective and prospective trials demonstrating benefit of reduced doses or dose escalation are accumulating. #meded #gionc #crcsm #pancsm

Even after cancer treatment ends, the fear that it might return can feel heavy and persistent. Join Karen Sheinkopf, LCSW and Michael Shusterman, MD (@guildsman) to learn how to cope with fear of #recurrence & #scanxiety in cancer #survivorship. RSVP: https://t.co/sodTghZRnL

1/n X-torial: It seems the biomedical field needs some help in understanding the @Nature paper on RT induced amphiregulin effects in cancer recently published. https://t.co/uWrUEkOOfp @ASCO @myESMO #misinformation #fakenews @TylerSbrt @DrewMoghanaki

We are recruiting @Perlmutter_CC ! Feel free to DM/contact me for details! Gastrointestinal Medical Oncology Faculty Physician - focused at our NYU Langone Hospital – Long Island campus in Mineola NY. Fantastic opportunity to join growing program, including new GI Cancer Center.

If Exercise Were a Pill, We'd All Prescribe It to Patients With Cancer. But It's Not | Journal of Clinical Oncology

New in @JCOPO_ASCO Our @MayoCancerCare read world data on ICIs for early stage dMMR GEA High pCR, high cCR, and real feasibility of non-operative management using ICI monotherapy. @GIcancerDoc @Ahn_Daniel_Onc https://t.co/gLXPxu6GG4

💉Peg-GCSF prophylaxis vs no prophylaxis in 1L mFOLFIRINOX of pancreatic cancer @eClinicalMed ➡️Phase II ✅G3–4 neutropenia 2.6% vs. 38.5%, P = 0.0001 ✅Febril neutropenia 0% vs 12.8% 👉 https://t.co/Ca0CmSvPHa #cancer #oncology #MedX #PancreaticCancer @OncoAlert

Disappointing update: FORTITUDE-102 (chemo + nivo ± bemarituzumab) in metastatic gastric cancer has been halted by @Amgen. Another setback for FGFR2b-targeted strategies in the 1L setting. #GastricCancer #GIOnc #FGFR2b https://t.co/AENyNqShbl

Important paper. The dogma/SOC is locally recurrent or persistent anal SCC requires APR, but some pts decline surgery or tumors inoperable. In this series, 39Gy in 1.5Gy BID lead to CR in 46%, suggesting many tumors still radiosensitive & reRT can achieve durable LC. @OncoAlert

DID YOU KNOW ... that leukocytosis can take years to resolve after smoking cessation? Why? Because smoking reprograms hematopoietic stem cells toward myeloid output. Those epigenetic changes wash out slowly as new stem-cell generations replace the old.

Good news!🧪 🩸Serum 5-HIAA performs as well as 24h-urine test for carcinoid syndrome - faster, easier & more patient-friendly 🔹 AUROC ~0.82–0.92 (equivalent) 🔹 Optimal cutoff: 139 nmol/L 🔹 Correlates with symptoms Should it be new standard?🤔🦓 🔗 https://t.co/u3Nd5plxOh

We are recruiting!  Feel free to DM/contact me! Heme Malignancies/Stem Cell Transplant/Cell Therapy Assist/Assoc/Full Professor Faculty in Heme Malignancies and/or Cellular Therapy/Stem Cell Transplant (including leadership roles) primarily at NYU Langone Hospital-Long Island

Very interesting data. Confirms clinically what we have seen in clinic @Perlmutter_CC that individuals with lung only recurrences in PDAC do much better for unclear reasons. There must be a unique biology to these lung metastases.

Watch-and-wait approach in high-risk locally advanced rectal cancer: outcomes after complete response to total neoadjuvant therapy ➡️ https://t.co/zumOOVefkk This study supports the safety of a watch-and-wait approach in patients with high-risk rectal cancer with a complete

#BoneMetastases in #NETs Very interesting topic @OncoThor 😊 We did perform an in depth review of the literature, not much changed since 👉 https://t.co/2CMuztBAmn Our own @TheChristieNHS experience published too 👉 https://t.co/hwtlTtDhGr @MGMcNamara @ENETS_ORG @GrupoGetne

Bone mets (BM) are common in patients with well diff NETs and have been associated with shorter OS. Once routine use of SSTR PET imaging began, we have diagnosed many more patients with BM. This study shows that BM are detected in 1/3 of small bowel NETs and more commonly seen

The human crisis in #cancer: a Lancet Oncology Commission. https://t.co/6zS7YY4UYe @TheLancet @TheLancetOncol #PallOnc #FinancialToxicity #SuppOnc @BillyRosaPhD @ZimmTeamLab

@DraMartinezLago @myESMO @ESMO_Open @GrupoTTD @Erman_Akkus @OncoAlert @colontown @FightCRC @marklewismd @oncodaily @Larvol @OncBrothers @mtmdphd @RenoHemonc @SuyogCancer @GlopesMd We also addressed this🙋🏻‍♂️in this editorial at @NatureMedicine. bTMB ≠ tTMB It’s a whole different issue on how bad TMB is as a marker for immunotherapy for patients with colorectal cancer. However, even if you are going to use it, don’t in these post EGFR⛔️cases. @OncoAlert

We looked at this exact question and found that high TMB after targeted therapy, which is more striking in plasma than in tissue, is not sufficient to engender a response to immunotherapy. Manuscript just out!

Fear of cancer recurrence is real and can impact quality of life. @Perlmutter_CC is hosting survivorship webinar with my colleagues Dr. Michael Shusterman @guildsman and social worker Karen Sheinkopf. #survivorship https://t.co/b6EoF4Zgez

Cancer #survivorship comes with a new set of challenges — especially when it comes to planning for future health needs. Join Dr. Olivia Seecof to learn how #AdvanceCarePlanning (ACP) empowers survivors to take control of their healthcare decision. RSVP: https://t.co/bwzduUgf3V